Sven Stegemann
- Pharmaceutical Science top 0.5%
- Materials Chemistry
- Pediatrics, Perinatology and Child Health top 5%
- Molecular Biology
- Pulmonary and Respiratory Medicine
- Co-authors
- Hans H. LindénF. LeveillerD. FranchiHidde de JongJörg BreitkreutzM. GoschDiana A. van Riet‐NalesAmrit Paudel
- Topics
- Health Systems, Economic Evaluations, Quality of Life (16 papers)Pharmaceutical Practices and Patient Outcomes (13 papers)Pharmaceutical studies and practices (11 papers)
- Journals
- International Journal of PharmaceuticsDrug Discovery TodayColloids and Surfaces B Biointerfaces
- Partner nations
- AustriaUnited KingdomGermany
In The Last Decade
Sven Stegemann
49 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 155
- Pharmaceutical Science 712
- Materials Chemistry 304
- Pediatrics, Perinatology and Child Health 285
- Molecular Biology 212
- Pulmonary and Respiratory Medicine 196
Countries citing papers authored by Sven Stegemann
This map shows the geographic impact of Sven Stegemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Stegemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Stegemann more than expected).
Fields of papers citing papers by Sven Stegemann
This network shows the impact of papers produced by Sven Stegemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Stegemann. The network helps show where Sven Stegemann may publish in the future.
Co-authorship network of co-authors of Sven Stegemann
This figure shows the co-authorship network connecting the top 25 collaborators of Sven Stegemann. A scholar is included among the top collaborators of Sven Stegemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Stegemann. Sven Stegemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 37 | |
| 5 | 6 | |
| 6 | 29 | |
| 7 | 6 | |
| 8 | 13 | |
| 9 | 12 | |
| 10 | 88 | |
| 11 | 15 | |
| 12 | 65 | |
| 13 | Increasing complexity of drug therapy in older adults and the importance of adherence monitoring | 1 |
| 14 | 8 | |
| 15 | 19 | |
| 16 | 7 | |
| 17 | 166 | |
| 18 | 15 | |
| 19 | Self-Emulsifying Drug Delivery Systems: Facing the bioavailability challenge in drug delivery | 0 |
| 20 | Colored capsules - : a contribution to drug safety | 12 |
About Sven Stegemann
Sven Stegemann is a scholar working on Geriatrics and Gerontology, Family Practice and Pharmaceutical Science, having authored 50 papers that have together received 1.9k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Pharmaceutical Practices and Patient Outcomes (13 papers) and Pharmaceutical studies and practices (11 papers). The work is most often cited by research in Pharmaceutical Science (712 citations), Geriatrics and Gerontology (164 citations) and Family Practice (87 citations). Sven Stegemann has collaborated with scholars based in Austria, United Kingdom and Germany. Frequent co-authors include Hans H. Lindén, F. Leveiller, D. Franchi, Hidde de Jong, Jörg Breitkreutz, M. Gosch, Diana A. van Riet‐Nales, Amrit Paudel, Massimo Bresciani and Mansoor A. Khan. Their work appears in journals such as International Journal of Pharmaceutics, Drug Discovery Today and Colloids and Surfaces B Biointerfaces.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.